GAMMA GLOBIN VECTORS FOR TREATMENT OF HEMOGLOBINOPATHIES

用于治疗血红蛋白病的伽马珠蛋白载体

• 批准号: 6629108
• 负责人: DEREK A PERSONS
• 金额: $ 12.37万
• 依托单位: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-02-01 至 2004-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6629108
• 关键词: NOD mouse; SCID mouse; bone marrow transplantation; clinical research; colony stimulating factor; cord blood; disease /disorder model; gene therapy; globin; hematopoiesis; hematopoietic stem cells; hemoglobinopathy; human subject; human tissue; nonhuman therapy evaluation; technology /technique development; thalassemia; tissue /cell culture; transfection /expression vector

This application is focused on the candidate's immediate career goal, which is to enhance and further his laboratory-based training to date by acquiring new skills in the development, testing and use of globin vectors designed for gene therapy approaches to the beta-chain hemoglobinopathies. With the applicant's clinical background, previous doctoral research experience and three years of post-doctoral work in the laboratory of Dr. Arthur Nienhuis at St. Jude Children's Research Hospital (SJCRH) most recently, the candidate is now entering a transitional phase in his career with the goal of becoming an independent investigator as a clinician-scientist. However, the candidate and the sponsor strongly believe that further training involving the new vectors and animal models outlined in this application will facilitate this transition and greatly enhance the potential for early success as an independent investigator. As an independent faculty member in an academic medical setting, it is the candidate's long-term career goal to continue in the area of gene therapy for hematologic disorders with specific interest in developing a research program compatible with the translation of successful preclinical gene therapy approaches to the clinic. In this application, the candidate proposes to obtain additional training and specific expertise in the development and testing of new therapeutic globin vectors with his current mentor, Dr. Arthur Nienhuis, at SJCRH. Within the Div. of Experimental Hematology in which Dr. Nienhuis is a member and Chief, there is significant expertise in retroviral and lentiviral vector development, in techniques of gene transfer into murine and human hematopoietic stem cells, in animal models of thalassemia, and in the use of the NOD/SCID murine transplant model for human stem cells. Thus, the further training the applicant requires for the execution of the proposed research is readily available. The proposed research project is based on the need for the development of improved globin vectors for use in a gene therapy approach to both thalassemia and sickle cell anemia. The focus of this project involves a gene addition strategy based on the hypothesis that delivery of an optimized gamma-globin gene cassette can achieve a sufficient level of expression in developing erythroid cells to reverse the thalassemic or sickle cell disease phenotype. The project contains 3 specific aims: 1) to design and test novel gamma-globin retroviral and lentiviral vectors, 2) to use a murine model of beta-thalassemia to model gene therapy approaches using optimized gamma-globin vectors. and 3) to characterize and use primitive hematopoietic cells from patients with beta-thalassemia to evaluate the therapeutic potential of optimized gamma-globin vectors.

该申请侧重于候选人的近期职业目标，即通过获得用于β链血红蛋白病基因治疗方法的珠蛋白载体的开发，测试和使用方面的新技能，加强和进一步他迄今为止的实验室培训。 凭借申请人的临床背景，之前的博士研究经验以及最近在St. Jude儿童研究医院（SJCRH）亚瑟Nienhuis博士实验室的三年博士后工作，候选人现在正进入职业生涯的过渡阶段，目标是成为一名独立的研究者，成为一名临床科学家。 然而，候选人和申办方坚信，涉及本申请中概述的新载体和动物模型的进一步培训将促进这一转变，并大大提高作为独立研究者早期成功的可能性。作为学术医疗环境中的独立教员，候选人的长期职业目标是继续从事血液病基因治疗领域的研究，并对开发与成功的临床前基因治疗方法翻译兼容的研究项目感兴趣。 在此申请中，候选人建议在SJCRH与他目前的导师亚瑟·尼恩霍伊斯博士一起获得新治疗性珠蛋白载体开发和测试方面的额外培训和特定专业知识。 在Div。Nienhuis博士是实验血液学的成员和主任，在逆转录病毒和慢病毒载体开发、基因转移到小鼠和人类造血干细胞中的技术、地中海贫血动物模型以及NOD/SCID小鼠移植模型用于人类干细胞方面具有重要的专业知识。 因此，申请人执行拟议研究所需的进一步培训是现成的。 拟议的研究项目是基于需要开发用于地中海贫血和镰状细胞性贫血基因治疗方法的改进珠蛋白载体。该项目的重点涉及一种基因添加策略，该策略基于以下假设：递送优化的γ-珠蛋白基因盒可以在发育中的红系细胞中实现足够的表达水平，以逆转地中海贫血或镰状细胞病表型。 该项目包含3个具体目标：1）设计和测试新型γ-珠蛋白逆转录病毒和慢病毒载体，2）使用β-地中海贫血的小鼠模型来模拟使用优化的γ-珠蛋白载体的基因治疗方法。和3）表征和使用来自β-地中海贫血患者的原始造血细胞来评估优化的γ-珠蛋白载体的治疗潜力。